10-Q: Silexion Therapeutics Q2 Loss Widens Amid Funding Efforts

Silexion Therapeutics reported an increased net loss in Q2 2025, actively pursuing multiple financing strategies and navigating Nasdaq listing compliance challenges.

Summary

• Net loss for the six months ended June 30, 2025, increased to $4.238 million, up from $2.912 million in the prior year period.
• Operating loss for the six months ended June 30, 2025, was $3.934 million, compared to $2.635 million for the same period in 2024.
• General and administrative expenses surged by 155.6% to $2.3 million for the six months ended June 30, 2025, primarily due to increased headcount, salaries, and professional services costs associated with operating as a public company.
• Research and development expenses decreased by 5.9% to $1.6 million for the six months ended June 30, 2025, mainly due to changes in subcontractor and consultant timing, partially offset by increased payroll.
• Cash and cash equivalents stood at $3.466 million as of June 30, 2025, an increase from $1.187 million at December 31, 2024.
• Shareholders' equity improved from a capital deficiency of $(3.989) million at December 31, 2024, to positive equity of $120 thousand at June 30, 2025.
• The company has not generated any revenue to date and expects to continue incurring significant operating losses.
• A 1-for-15 reverse share split was effected on July 28, 2025, to address Nasdaq's bid price deficiency.
• The company received a favorable decision from the Nasdaq hearings panel on July 7, 2025, allowing continued listing on the Nasdaq Capital Market, conditioned on achieving at least $2.5 million in shareholders' equity by September 19, 2025.

Sentiment

Score: 3

Explanation: While the company has successfully raised capital and is actively working to maintain its Nasdaq listing, the substantial increase in net and operating losses, coupled with a significant cash burn and explicit 'going concern' doubt, indicates a highly precarious financial position. The repeated need for reverse share splits and warrant inducement transactions points to ongoing dilution and challenges in sustaining shareholder value.

Positives

• Shareholders' equity improved from a capital deficiency of $(3.989) million at December 31, 2024, to positive equity of $120 thousand at June 30, 2025.
• Successfully raised approximately $5.0 million gross proceeds from a public offering in January 2025.
• Generated additional gross proceeds of $3.3 million and $1.8 million from induced warrant exercise transactions in January and August 2025, respectively.
• Secured $3.1 million through the Equity Line of Credit (ELOC) agreement with White Lion Capital, LLC.
• Received a favorable decision from the Nasdaq hearings panel on July 7, 2025, allowing continued listing on the Nasdaq Capital Market, subject to conditions.
• Shareholders approved an increase in the 2024 Equity Incentive Plan by 84,791 ordinary shares on July 14, 2025, increasing the total pool to 86,568 shares.

Negatives

• Net loss increased by 44.8% for the six months ended June 30, 2025, compared to the prior year, reaching $4.238 million.
• Operating loss increased significantly for both the six-month and three-month periods ended June 30, 2025.
• General and administrative expenses increased substantially by 155.6% for the six-month period, driven by public company costs.
• Net cash used in operating activities increased by 78.6% to $5.0 million for the six months ended June 30, 2025.
• The company has never generated revenue from product sales and expects to continue incurring significant losses.
• Substantial doubt exists about the company's ability to continue as a going concern for at least 12 months.
• Received a Nasdaq bid price deficiency notice on July 18, 2025, requiring a reverse share split to maintain compliance.
• Current cash and cash equivalents are estimated to fund operations only into the first quarter of 2026.

Risks

• Substantial doubt exists about the ability to continue as a going concern for at least 12 months due to recurring losses and negative operating cash flows.
• Need to raise substantial additional funding, which may not be available on acceptable terms or at all, leading to dilution for shareholders.
• Risk of delisting from Nasdaq if the company fails to meet the $2.5 million shareholders' equity requirement by September 19, 2025, or other listing rules.
• The approach to discover and develop novel RNAi therapeutics is unproven for oncology and may never lead to marketable products.
• Lack of experience producing product candidates at commercial levels and no marketing/sales organization.
• Uncertain market receptiveness, insurance coverage, and reimbursement for potential products.
• Inability to attract, develop, or retain key personnel or additional employees.
• Potential for significant dilution from future equity issuances, including remaining ELOC shares, warrants, and the A&R Sponsor Promissory Note.
• Ongoing geopolitical instability in Israel, including the war with Hamas and potential escalation with other regional actors, could impact operations, despite current immaterial effects.

Future Outlook

The company expects to continue incurring significant expenses and operating losses for the foreseeable future as it advances the development of SIL204, initiates pre-clinical and clinical trials, and invests in potential additional pipeline products. Expenses are anticipated to increase with further development, regulatory approvals, intellectual property protection, increased headcount, and public company operational costs. The company will need substantial additional funding beyond its current cash, which is estimated to last only into the first quarter of 2026. Future financing is expected through public and private equity offerings, debt financings, strategic alliances, and licensing arrangements, with a focus on meeting Nasdaq's $2.5 million shareholders' equity requirement by September 19, 2025.

Management Comments

• We expect to continue to incur significant expenses and operating losses for the foreseeable future.
• We anticipate that our expenses will increase if and as we: apply for Orphan Drug Designation... conduct toxicological studies... initiate a clinical trial powered for statistical significance... seek marketing approvals... maintain, expand and protect our intellectual property portfolio; hire additional operational, clinical, quality control and scientific personnel; add additional product candidates to our pipeline; add operational, financial and management information systems and personnel... and invest in research and development and regulatory approval efforts...
• We intend to achieve at least $2.5 million of shareholders equity by September 19, 2025 and sustain that minimum level of shareholders equity on an ongoing basis, thereby complying with the condition set by the hearings panel for maintaining our Nasdaq listing.
• Our issuance of equity securities in value-enhancing transactions, whether extraordinary or ordinary-course, will serve as the primary means by which we can effectively achieve that goal, and we will need additional authorized share capital in order to do so.
• Based on our current business plan, we believe our current cash and cash equivalents, and anticipated cash flow from operations, will not be sufficient to meet our anticipated cash requirements for the next 12 months from the date of this quarterly report.

Industry Context

Silexion operates in the highly competitive and capital-intensive clinical-stage oncology biotechnology sector, specifically targeting KRAS-driven cancers with siRNA technology. This approach, focusing on silencing the oncogene rather than inhibiting the protein, represents a differentiated strategy within the broader oncology landscape. The company's challenges with sustained profitability and ongoing capital requirements are typical for early-stage biotech firms that have not yet brought a product to market. The need for continuous funding for R&D and clinical trials is a common characteristic of this industry, where significant investment is required before potential revenue generation.

Comparison to Industry Standards

• As a clinical-stage biotechnology company with no revenue, Silexion's financial profile (significant operating losses, negative cash flow from operations, and reliance on external financing) is typical for companies at this stage of development.
• The need for continuous capital raises, including equity lines of credit and warrant inducement transactions, is a common strategy for early-stage biotech companies to fund expensive R&D and clinical trials.
• The challenges with Nasdaq listing requirements, particularly regarding minimum share price and market value, are not uncommon for smaller, development-stage companies, especially after reverse share splits.
• The company's focus on siRNA for KRAS-driven cancers positions it in a competitive but high-potential area, similar to other biotech firms exploring novel therapeutic modalities for difficult-to-treat cancers. Specific comparable companies or projects are not mentioned in the filing, so a direct comparison is not possible.

Corporate Governance

Related Party Transactions

• Research and development expenses included $0 (2025) and $34 thousand (2024) from related parties for the six-month periods.
• General and administrative expenses included $58 thousand (2025) and $24 thousand (2024) from related parties for the six-month periods.
• Financial expenses included $229 thousand (2025) and $135 thousand (2024) from related parties for the six-month periods.
• Private warrants to purchase ordinary shares included an amount less than $1 (2025) and $1 thousand (2024) due to related party.
• Non-Current liabilities include a Related Party Promissory Note (Sponsor Promissory Note) of $3,190 thousand (June 30, 2025) and $2,961 thousand (December 31, 2024).
• The A&R Sponsor Promissory Note of $3,433,000 was issued to the Moringa sponsor.

Stakeholder Impact

• Shareholders face significant dilution from ongoing and future equity raises (public offerings, warrant exercises, ELOC), and reverse share splits. There is a risk of further share price depreciation and potential delisting.
• Employees may benefit from increased headcount and salaries, and the equity incentive plan increase, but also face uncertainty due to the 'going concern' doubt.
• Creditors, including holders of promissory notes and lease obligations, face risk due to the 'going concern' doubt.
• Customers/Patients could potentially benefit from new treatments for KRAS-driven cancers if SIL204 development is successful, but this is a long-term, high-risk endeavor.

Next Steps

• Demonstrate restoration of compliance with Nasdaq's $2.5 million shareholders' equity requirement by September 19, 2025.
• Seek shareholder approval for an increase in authorized share capital at the extraordinary general meeting on August 12, 2025.
• Conduct additional financing activities to fund operations and meet Nasdaq listing conditions.
• Apply for Orphan Drug Designation in the U.S. and EU for SIL204.
• Conduct toxicological studies with respect to SIL204.
• Initiate a clinical trial powered for statistical significance with respect to SIL204.
• Seek marketing approvals for SIL204 in various territories.
• Maintain, expand, and protect the intellectual property portfolio.
• Hire additional operational, clinical, quality control, and scientific personnel.
• Add additional product candidates to the pipeline.
• Add operational, financial, and management information systems and personnel.
• Invest in research and development and regulatory approval efforts to utilize technology as a platform.

Key Dates

Recommendation

The company faces severe financial distress, evidenced by increasing net losses, significant cash burn, and an explicit 'going concern' warning from management and auditors. While recent capital raises provide temporary liquidity, they come at the cost of substantial shareholder dilution, as further evidenced by multiple reverse share splits and ongoing warrant inducement transactions. The company's continued struggle to meet Nasdaq listing requirements, despite a favorable panel decision, highlights persistent operational and financial instability. Without a clear path to profitability or sustainable funding, the risk of further value erosion and potential delisting remains exceptionally high, making it an unfavorable investment.

Keywords

Silexion Therapeutics, SLXN, biotechnology, oncology, KRAS, siRNA, pancreatic cancer, SIL204, Nasdaq listing, going concern, capital raise, warrants, reverse share split, SEC filing, Q2 2025 earnings, financial results